Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 3.47B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -265.44M |
| Shares Out | 147.37M |
| EPS (ttm) | -1.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $22.52 |
| Previous Close | $22.92 |
| Change ($) | -0.40 |
| Change (%) | -1.75% |
| Day's Open | 22.95 |
| Day's Range | 22.49 - 23.51 |
| Day's Volume | 1,375,800 |
| 52-Week Range | 15.88 - 54.21 |
SAN CARLOS, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report i...
The biopharma outfit has put some red flags in the rearview mirror, and sees a plausible approval on the horizon.
Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.
SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced tha...
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced clinical data for its tumor-infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC). The co...
21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies Including Immunotherapy
This biotech's fumble has caught the attention of a fund manager known for making innovative investments.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced updated clinical data for lifileucel from Cohort 2 of C-144-01 clinical study in patients with advanced melanoma. Data were presented at the ASCO 202...
Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study
86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study
SAN CARLOS, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...
Cathie Wood-led Ark Investment Management is betting that despite recent setbacks Iovance Biotherapeutics Inc (NASDAQ: IOVA) will benefit from its compelling tumor-infiltrating lymphocyte (TIL) immunoth...
The CEO's unexplained departure has left investors scratching their heads.
A couple of the ARK exchange-traded funds run by ETF star Cathie Wood made huge purchases on Thursday.
SAN FRANCISCO, May 20, 2021 /PRNewswire/ -- Hagens Berman urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) investors with significant losses to submit your losses now. The firm is investigating possib...
Yesterday the FDA asked Iovance Biotherapeutics Inc (NASDAQ: IOVA) for more data on the assays for lifileucel US application. Now the company announced additional clinical data for lifileucel alone and ...
Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.
MILWAUKEE, May 20, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Iovance (NASDAQ: IOVA). The investigation results from inaccurate statements Iovance may have...
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
LOS ANGELES--(BUSINESS WIRE)---- $IOVA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors
86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study
In a brief statement, Iovance Biotherapeutics Inc (NASDAQ: IOVA) company divulged that the FDA wants to see more data on the assays used to ensure each batch of its tumor-infiltrating lymphocyte therapy...
The company is delaying the FDA approval filing for cell therapy lifileucel.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has received regulatory feedback from the FDA on its potency assays for lifileucel. Following FDA feedback, Iovance will have to submit additional assay data a...
SAN CARLOS, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announce...
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up
Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.
Expanding First-in-Class TIL Cell Therapy Platform for Solid Tumors Expanding First-in-Class TIL Cell Therapy Platform for Solid Tumors
SAN CARLOS, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announce...
Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study
SAN CARLOS, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report ...
Median Duration of Response Not Reached at 28.1 Months of Median Study Follow Up in Cohort 2 of C-144-01 Study
TIL therapy looks able to win a large addressable market, and Iovance is the leader of the pack.
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...
SAN CARLOS, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...
SAN CARLOS, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...
Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.
Advancing First-in-Class TIL Cell Therapy for Solid Tumors Advancing First-in-Class TIL Cell Therapy for Solid Tumors
SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report i...
SAN CARLOS, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...
Iovance is ramping up tumor-infiltrating lymphocytes as an ingenious way to eradicate cancers. As such, I believe it'll continue to deliver stellar data. Riding robust data, LPN-145 and lifileucel, are ...
SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...
SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...
Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.
About IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastat... [Read more...]
| Industry Biotechnology | Founded 2007 |
| CEO Maria Fardis | Employees 241 |
| Stock Exchange NASDAQ | Ticker Symbol IOVA |
Analyst Forecasts
According to 12 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price forecast is 40.31, which is an increase of 79.00% from the latest price.